斯必申品牌怎么样

具备多剂型品种的生产能力和全方位的药物研发能力，集研发/生产/销售中西原料药及制剂的综合型医药企业

四川美大康华康药业有限公司是一家集研发、生产、销售的化学制药企业，由北京金源耀业医药技术有限公司、四川美大康药业集团、四川剑南春集团等共同投资。公司位于四川绵竹经济开发区江苏工业园。

公司剂型产品齐全，涵盖冻干粉针剂、无菌粉针剂、大容量注射剂、小容量注射剂、滴眼剂、溶液剂（含雾化吸入）、片剂、胶囊剂、外搽剂以及化学原料药。现有120多个药品批准文号，70多个国家基本药物品种，12个新药证书（包括三个一类新药证书），主要品种以生产、销售抗菌药（抗细菌、真菌、厌氧菌）、抗病毒药、维生素、解热镇痛等治疗类别为主。

公司一贯注重企业发展和品质，2012年公司投资3亿进行技术改造，建成四万多平方米的综合制药生产厂房，同时与北京福瑞康正医药技术研究所、山东达冠医药技术研究所合作，布局十大治疗领域品种为方向。截止2016年6月，已申报42个新药，获得32个临床批件，有26个品种在进行BE和临床研究中。华康药业已具备了多剂型品种的生产能力和药物研发能力，在未来3～5年华康药业将步入高速、持续发展之路。

四川美大康华康药业未来坚定走创新产品、创新发展之路，持续改进生产质量管理体系，谋求新的跨越式发展。

Sichuan meidakang Huakang Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating R & D, production and sales of Chinese and Western APIs and preparations. It is composed of Beijing jinyuanyao Pharmaceutical Technology Co., Ltd., Sichuan meidakang Pharmaceutical Group, Sichuan Jiannanchun Group, etc Same investment. The company is located in Jiangsu Industrial Park, Mianzhu Economic Development Zone, Sichuan Province. The company has a complete range of dosage forms, including freeze-dried powder injection, sterile powder injection, large volume injection, small volume injection, eye drops, solutions (including atomized inhalation), tablets, capsules, external liniments and chemical APIs. There are more than 120 drug approval numbers, more than 70 national basic drug varieties, and 12 new drug certificates (including three first-class new drug certificates). The main varieties are mainly the production and sales of antibacterial drugs (anti bacteria, fungi, anaerobic bacteria), antiviral drugs, vitamins, antipyretic and analgesic treatment categories. The company has always paid attention to the development and quality of the enterprise. In 2012, the company invested 300 million yuan to carry out technical transformation, built a comprehensive pharmaceutical production plant of more than 40000 square meters, and cooperated with Beijing Furui Kangzheng Pharmaceutical Technology Research Institute and Shandong Daguan Pharmaceutical Technology Research Institute to layout ten major treatment areas. As of June 2016, 42 new drugs have been applied, 32 clinical approvals have been obtained, and 26 varieties are in be and clinical research. Huakang pharmaceutical industry has the production capacity of multiple dosage forms and drug research and development capacity. In the next 3 to 5 years, Huakang pharmaceutical industry will step into a high-speed and sustainable development path. In the future, Sichuan meidakang Huakang Pharmaceutical Co., Ltd. will firmly follow the road of innovative products and development, continuously improve the production quality management system, and seek new leapfrog development.

本文链接： https://brand.waitui.com/2073bbdc7.html 联系电话：0838-3216800